These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 18700727

  • 1. Use of multidimensional fluorescence resonance energy transfer to establish the orientation of cholecystokinin docked at the type A cholecystokinin receptor.
    Harikumar KG, Gao F, Pinon DI, Miller LJ.
    Biochemistry; 2008 Sep 09; 47(36):9574-81. PubMed ID: 18700727
    [Abstract] [Full Text] [Related]

  • 2. Measurement of intermolecular distances for the natural agonist Peptide docked at the cholecystokinin receptor expressed in situ using fluorescence resonance energy transfer.
    Harikumar KG, Pinon DI, Wessels WS, Dawson ES, Lybrand TP, Prendergast FG, Miller LJ.
    Mol Pharmacol; 2004 Jan 09; 65(1):28-35. PubMed ID: 14722234
    [Abstract] [Full Text] [Related]

  • 3. Fluorescence resonance energy transfer analysis of the antagonist- and partial agonist-occupied states of the cholecystokinin receptor.
    Harikumar KG, Miller LJ.
    J Biol Chem; 2005 May 13; 280(19):18631-5. PubMed ID: 15757907
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Ligand-induced internalization of the type 1 cholecystokinin receptor independent of recognized signaling activity.
    Cawston EE, Harikumar KG, Miller LJ.
    Am J Physiol Cell Physiol; 2012 Feb 01; 302(3):C615-27. PubMed ID: 22049215
    [Abstract] [Full Text] [Related]

  • 9. Refinement of the structure of the ligand-occupied cholecystokinin receptor using a photolabile amino-terminal probe.
    Ding XQ, Dolu V, Hadac EM, Holicky EL, Pinon DI, Lybrand TP, Miller LJ.
    J Biol Chem; 2001 Feb 09; 276(6):4236-44. PubMed ID: 11050076
    [Abstract] [Full Text] [Related]

  • 10. Differential docking of high-affinity peptide ligands to type A and B cholecystokinin receptors demonstrated by photoaffinity labeling.
    Dong M, Liu G, Pinon DI, Miller LJ.
    Biochemistry; 2005 May 03; 44(17):6693-700. PubMed ID: 15850403
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Molecular basis for benzodiazepine agonist action at the type 1 cholecystokinin receptor.
    Harikumar KG, Cawston EE, Lam PCH, Patil A, Orry A, Henke BR, Abagyan R, Christopoulos A, Sexton PM, Miller LJ.
    J Biol Chem; 2013 Jul 19; 288(29):21082-21095. PubMed ID: 23754289
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Direct demonstration of unique mode of natural peptide binding to the type 2 cholecystokinin receptor using photoaffinity labeling.
    Dong M, Miller LJ.
    Peptides; 2013 Aug 19; 46():143-9. PubMed ID: 23770253
    [Abstract] [Full Text] [Related]

  • 19. Differential spatial approximation between cholecystokinin residue 30 and receptor residues in active and inactive conformations.
    Dong M, Hadac EM, Pinon DI, Miller LJ.
    Mol Pharmacol; 2005 Jun 19; 67(6):1892-900. PubMed ID: 15774770
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.